Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma

Background Polyclonal autologous T cells that are epigenetically reprogrammed through mTOR inhibition and IFN-α polarization (RAPA-201) represent a novel approach to the adoptive T cell therapy of cancer. Ex vivo inhibition of mTOR results causes a shift towards T central memory (TCM) whereas ex viv...

Full description

Saved in:
Bibliographic Details
Main Authors: Lawrence G Lum, Parameswaran Hari, Aniko Szabo, Michele Donato, Jee Hyun Park, Daniel H Fowler, Binod Dhakal, Saurabh Chhabra, Deborah D Glass, David S Siegel, Tania C Felizardo
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/1/e010649.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/1/e010649.full

Similar Items